Promimic AB (publ)

Welcome to our presentation of the third quarter of 2025. One that goes to the books as the best so far. What is it you want to highlight, Magnus?

I want to highlight that we have an increase of 21% and that we are growing with 32% in the currency market. And another important thing to highlight is that the revenue from the implant business, our core business, is growing by a whole 51%. Our customers have We have received five new products approved on the market and in total we now have 73 products with our technology that are approved for clinical use. Another important thing is that during the month of August our process installation in Warsaw, Indiana was approved and validated to be used. This means that MPI This new facility will increase its capacity three times compared to the current situation. This means that we can receive work from the largest customers on the market and we are ready to scale up both the business and process customer implants. Can you tell us a little more about the numbers?

Of course. The sales fell to 12.9 million kronor, or 14.1 million kronor, and that is 21% growth and 32% interest rates. The result before the deadline was 254,000 kronor negative, and the cash flow has also decreased in the quarter and fell to minus 3.5 million kronor. If we only look at the ongoing business, it is a clear improvement both in the quarter and in the whole year. And in the whole year, we double our development costs to invest in future growth. Can you tell us more about the five new products that have been approved?